In countries in which new life-sustaining drugs cannot be patented, such drugs are sold at widely affordable
prices; those same drugs, where patented, command premium prices because the patents shield patent-holding
manufacturers from competitors. These facts show that future access to new life-sustaining drugs can be
improved if the practice of granting patents on newly developed life-sustaining drugs were to be abolished
everywhere. Which of the following, if true, most seriously weakens the argument?
A. In countries in which life-sustaining drugs cannot be patented, their manufacture is nevertheless a profitable
enterprise.
B. Countries that do not currently grant patents on life-sustaining drugs are, for the most part, countries with large
populations.
C. In some countries specific processes for the manufacture of pharmaceutical drugs can be patented even in
cases in which the drugs themselves cannot be patented.
D. Pharmaceutical companies can afford the research that goes into the development of new drugs only if patents
allow them to earn high profits.
E. Countries that grant patents on life-sustaining drugs almost always ban their importation from countries that do
not grant such patents.
OA is D.
I could not understand why C is wrong and why D is the answer.
My reasoning: if "SOME" countries can patent the process but not the drug itself, it may still not lead to improved access to life saving drugs. This I thought especially because the conclusion talks about abolishing the patents on these drugs "EVERYWHERE".
Is my line of thought correct? and could you explain both C and D options?
-Hitesh